688443.SHG Chongqing Genrix Biopharmaceutical Co. Ltd. A
- Market cap
- CNY 10.1B
- P/E
- -
- P/B
- 7.24x
- ROE
- -49.3%
- Dividend yield
- 0.30%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688443.SHG undervalued?
Graham numberThe Graham number of Chongqing Genrix Biopharmaceutical Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chongqing Genrix Biopharmaceutical Co. Ltd. A fundamental analysis
No fundamental analysis for Chongqing Genrix Biopharmaceutical Co. Ltd. A yet.
Chongqing Genrix Biopharmaceutical Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chongqing Genrix Biopharmaceutical Co. Ltd. A
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondyloarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family r…
Full company profileChongqing Genrix Biopharmaceutical Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chongqing Genrix Biopharmaceutical Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 39.2M | 475K | 1.21M | 30.1M | 231M | 306M |
| Gross Profit | 19.8M | -54.0K | 472K | 24.8M | 215M | 276M |
| Operating Income | -294M | -550M | -787M | -836M | -546M | -615M |
| EBITDA | - | -494M | -707M | -699M | -433M | -601M |
| Net Income | -322M | -576M | -801M | -797M | -536M | -632M |
| EPS | -1.17 | -2.10 | -2.19 | -2.17 | -1.46 | -1.72 |
| Balance Sheet | ||||||
| Total Assets | 1.00B | 962M | 3.59B | 3.15B | 2.99B | 2.74B |
| Total Liabilities | 691M | 933M | 810M | 1.02B | 1.41B | 1.46B |
| Shareholders' Equity | 312M | 29.1M | 2.78B | 2.13B | 1.58B | 1.28B |
| Cash & Short-term Investments | 14.1M | 49.3M | 2.89B | 2.04B | 1.54B | 527M |
| Cash Flow | ||||||
| Operating Cash Flow | -238M | -178M | -378M | -575M | -338M | - |
| Capital Expenditure | 113M | 146M | 91.0M | 45.3M | 85.4M | 91.1M |
| Free Cash Flow | -351M | -324M | -469M | -621M | -423M | -842M |
| Ratios | ||||||
| ROE | -103.3% | -1,981.9% | -28.8% | -37.5% | -33.8% | -49.3% |
| ROA | -32.1% | -59.9% | -22.3% | -25.3% | -17.9% | -23.1% |
| Net Profit Margin | -822.0% | -121,278.6% | -66,142.6% | -2,649.2% | -232.2% | -206.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Chongqing Genrix Biopharmaceutical Co. Ltd. A dividends
- Dividend yield
- 0.30%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 30.5M | 0.08 | - |
| 2024 | CNY 28.7M | 0.08 | - |
| 2023 | CNY 35.0M | 0.10 | - |
| 2022 | CNY 32.1M | 0.12 | - |
| 2021 | CNY 21.6M | 0.08 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Chongqing Genrix Biopharmaceutical Co. Ltd. A
- Insiders 69.99%
- Institutions 4.68%
- Public & others 25.33%
- Shares outstanding 367M
- Free float 67.4M
Chongqing Genrix Biopharmaceutical Co. Ltd. A company profile
- Company name
- Chongqing Genrix Biopharmaceutical Co. Ltd. A
- Ticker
- 688443.SHG
- ISIN
- CNE100006KG8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 984
- Fiscal year end
- December
- Address
- Building 2, Chongqing, China, 401338
- Phone
- 86 23 6175 8666
- Website
- genrixbio.com
About Chongqing Genrix Biopharmaceutical Co. Ltd. A
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondyloarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a monoclonal antibody for VZV infection; GR2302, a recombinant CD3xpMHC (HBV-S); GR2301, a recombinant anti-IL-15 monoclonal antibody; GR2304, a recombinant CD3xpMHC (PRAME); GR2502, a TCR-based antibody (TCRm); GR2603, a recombinant humanized trispecific antibody; GR1803, a bispecific antibody for multiple myeloma; GR1901, a bispecific antibody; WM202 a bispecific antibody; WM215, a single-domain antibody; GR1401, an anti-EGFR monoclonal antibody; and GR1405 an anti-PD-L1 monoclonal antibody. The company was founded in 2015 and is based in Chongqing, China.
Chongqing Genrix Biopharmaceutical Co. Ltd. A management
8- Mr. Zhigang LiuChairman, GM & Chief Scientific Officer · born 1973
- Mr. Liwen LiuCFO & Director · born 1991
- Mr. Zhiyuan ChangDeputy General Manager · born 1980
- Mr. Chunsheng LiSecretary of the Board, Deputy GM & Director · born 1990
- Mr. Wei WangDeputy General Manager · born 1979
- Ms. Xiao Yan HuangDeputy General Manager · born 1985
- Mr. Wei WangDeputy General Manager · born 1978
- Gui Mei DiaoAccounting Supervisor